Biomedical Engineering Reference
In-Depth Information
186. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R,
Albert V, et al. (2002) BLyS and APRIL form biologically
active heterotrimers that are expressed in patients with sys-
temic immune-based rheumatic diseases. J. Immunol. 169,
4314-4321.
187. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukow-
ski TR, et al. (2010) B-lymphocyte stimulator/a proliferation-
inducing ligand heterotrimers are elevated in the sera of
patients with autoimmune disease and are neutralized by
atacicept and B-cell maturation antigen-immunoglobulin.
Arthritis Res. Ther. 12, R48.
188. Steinberg MW, Shui JW, Ware CF, Kronenberg M. (2009)
Regulating the mucosal immune system: the contrasting roles
of LIGHT, HVEM, and their various partners. Semin. Immu-
nopathol. 31, 207-221.
189. Jeon ST, Kim WJ, Lee SM, Lee MY, Park SB, Lee SH, et al.
(2010) Reverse signaling through BAFF differentially
regulates the expression of inflammatory mediators and
cytoskeletal movements in THP-1 cells. Immunol. Cell.
Biol. 88, 148-156.
190. Sun M, Fink PJ. (2007) A new class of reverse signaling
costimulators belongs to the TNF family. J. Immunol. 179,
4307-4312.
191. Silva LC, Ortigosa LC, Benard G. (2010) Anti-TNF-alpha
agents in the treatment of immune-mediated inflammatory
diseases: mechanisms of action and pitfalls. Immunotherapy
2, 817-833.
192. Taga T, Narazaki M, Yasukawa K, Saito T, Miki D, Hama-
guchi M, et al. (1992) Functional inhibition of hematopoietic
and neurotrophic cytokines by blocking the interleukin 6
signal transducer gp130. Proc. Natl. Acad. Sci. USA 89,
10998-11001.
193. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S,
et al. (2000) Blockade of interleukin 6 trans signaling
suppresses T-cell resistance against apoptosis in chronic
intestinal inflammation: evidence in Crohn disease and exper-
imental colitis in vivo. Nat. Med. 6, 583-588.
194. T. Barkhausen, T. Tschernig, P. Rosenstiel, M. van Griensven,
R. P. Vonberg, M. Dorsch, A. Mueller-Heine, A. Chalaris,
J. Scheller, S. Rose-John, D. Seegert, C. Krettek, G. H.Waetzig.
(2011). Selective blockade of interleukin-6 trans-signaling
improves survival in a murine polymicrobial sepsis model.
Critical care medicine, 39, 1407-1413.
195. Jones SA. (2005) Directing transition from innate to
acquired immunity: defining a role for IL-6. J. Immunol.
175, 3463-3468.
196. Rose-John S, Schooltink H. (2007) Cytokines are a therapeu-
tic target for the prevention of inflammation-induced cancers.
Recent Results Cancer Res. 174, 57-66.
197. Silver JS, Hunter CA. (2010) gp130 at the nexus of inflamma-
tion, autoimmunity, and cancer. J. Leukoc. Biol. 88, 1145-1156.
198. Murakami M, Nishimoto N. (2011) The value of blocking
IL-6 outside of rheumatoid arthritis: current perspective.
Curr. Opin. Rheumatol. 23, 273-277.
199. Reichert JM. (2011) Antibody-based therapeutics to watch in
2011. MAbs 3, 76-99.
200. Nishimoto N. (2010) Interleukin-6 as a therapeutic target in
candidate inflammatory diseases. Clin. Pharmacol. Ther. 87,
483-487.
201. Schellekens H. (2002) Immunogenicity of therapeutic pro-
teins: clinical implications and future prospects. Clin. Ther.
24, 1720-1740; discussion 1719.
202. Schellekens H, Casadevall N. (2004) Immunogenicity of
recombinant human proteins: causes and consequences.
J. Neurol. 251(Suppl. 2), II4-II9.
203. Anderson P, Louie J, Lau A, Broder M. (2005) Mechanisms of
differential immunogenicity of tumor necrosis factor inhibi-
tors. Curr. Rheumatol. Rep. 7, 3-9.
204. Anderson PJ. (2005) Tumor necrosis factor inhibitors: clini-
cal implications of their different immunogenicity profiles.
Semin. Arthritis Rheum. 34, 19-22.
205. Buttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher
A, Jefferis R, et al. (2011) Taking immunogenicity assess-
ment of therapeutic proteins to the next level. Biologicals 39,
100-109.
206. Hofbauer LC, Schoppet M. (2004) Clinical implications of
the osteoprotegerin/RANKL/RANK system for bone and
vascular diseases. JAMA 292, 490-495.
207. Christen U, Thuerkauf R, Stevens R, Lesslauer W. (1999)
Immune response to a recombinant human TNFR55-IgG1
fusion protein: auto-antibodies in rheumatoid arthritis (RA)
and multiple sclerosis (MS) patients have neither neutralizing
nor agonist activities. Hum. Immunol. 60, 774-790.
208. Furst DE, Weisman M, Paulus HE, Bulpitt K, Weinblatt M,
Polisson R, et al. (2003) Intravenous human recombinant
tumor necrosis factor receptor p55-Fc IgG1 fusion protein,
Ro 45-2081 (lenercept): results of a dose-finding study in
rheumatoid arthritis. J. Rheumatol. 30, 2123-2126.
209. Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug
M, et al. (2003) Intravenous human recombinant tumor
necrosis factor receptor p55-Fc IgG1 fusion protein Ro
45-2081 (lenercept): a double blind, placebo controlled
dose-finding study in rheumatoid arthritis. J. Rheumatol.
30, 680-690.
210. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D,
Patel A, et al. (2007) The immunogenicity, safety, and
efficacy of etanercept liquid administered once weekly in
patients with rheumatoid arthritis. Clin. Exp. Rheumatol.
25, 40-46.
211. Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S.
(2007) Efficacy and safety of etanercept in psoriasis/psori-
atic arthritis: an updated review. Am. J. Clin. Dermatol. 8,
143-155.
212. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L,
Hanzatian DK, et al. (2009) Comparisons of affinities, avidi-
ties, and complement activation of adalimumab, infliximab,
and etanercept in binding to soluble and membrane tumor
necrosis factor. Clin. Immunol. 131, 308-316.
213. Devine EB, Alfonso-Cristancho R, Sullivan SD. (2011)
Effectiveness of biologic therapies for rheumatoid
arthritis: an indirect comparisons approach. Pharmaco-
therapy 31, 39-51.
Search WWH ::




Custom Search